Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 8Esophageal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Endometrial Neoplasms 1Endometrial Adenocarcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Bladder Urothelial Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Taxes 2Paclitaxel 2Immunoglobulin G 2Disulfides 2Carboplatin 2Bevacizumab 2trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1ixabepilone 1cediranib 1Trastuzumab 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1MK 2206 1GSK2141795 1Epothilones 1Cisplatin 1AZD 6244 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Endometrial Adenocarcinoma × Ogivri × Clear all
NCT00006089 2019-07-31

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
34 enrolled
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡